

# Enrico Munari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4247606/publications.pdf>

Version: 2024-02-01

83  
papers

3,905  
citations

117625

34  
h-index

138484

58  
g-index

84  
all docs

84  
docs citations

84  
times ranked

6345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. <i>Cellular and Molecular Immunology</i> , 2019, 16, 430-441.	10.5	327
2	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. <i>Frontiers in Immunology</i> , 2019, 10, 1179.	4.8	269
3	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. <i>Cancer Research</i> , 2013, 73, 7162-7167.	0.9	214
4	<sup>18</sup> F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	5.0	180
5	PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1113-1120.	1.1	135
6	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	5.5	135
7	Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma. <i>Urology</i> , 2015, 85, 703.e1-703.e6.	1.0	122
8	Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. <i>Modern Pathology</i> , 2011, 24, 1313-1319.	5.5	112
9	Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. <i>Mucosal Immunology</i> , 2016, 9, 1372-1383.	6.0	99
10	Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor in Exosome-Mediated Cytotoxicity against Tumor. <i>Cancers</i> , 2020, 12, 661.	3.7	96
11	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	1.8	89
12	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	3.7	85
13	Mit Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. <i>Cancers</i> , 2019, 11, 1110.	3.7	79
14	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1384-1389.	3.7	77
15	PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. <i>Oncolmmunology</i> , 2019, 8, 1557030.	4.6	76
16	High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. <i>Journal of Hematology and Oncology</i> , 2014, 7, 47.	17.0	66
17	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor. <i>International Journal of Cancer</i> , 2019, 145, 1660-1668.	5.1	65
18	Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 349-360.	2.9	65

#	ARTICLE	IF	CITATIONS
19	Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. <i>Histopathology</i> , 2016, 68, 422-432.	2.9	62
20	Human Innate Lymphoid Cells: Their Functional and Cellular Interactions in Decidua. <i>Frontiers in Immunology</i> , 2018, 9, 1897.	4.8	62
21	Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. <i>Human Pathology</i> , 2014, 45, 1130-1138.	2.0	61
22	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	4.1	61
23	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016, 11, 345-351.	3.6	56
24	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. <i>Frontiers in Immunology</i> , 2019, 10, 910.	4.8	54
25	NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. <i>Cancer Research</i> , 2018, 78, 3913-3925.	0.9	53
26	Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?. <i>Immunology Letters</i> , 2018, 201, 14-19.	2.5	50
27	Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. <i>Cancer Cytopathology</i> , 2019, 127, 52-61.	2.4	49
28	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 2156.	4.8	49
29	PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua. <i>Mucosal Immunology</i> , 2019, 12, 624-631.	6.0	45
30	Human papillomavirus infection and immunohistochemical p16INK4a expression as predictors of outcome in penile squamous cell carcinomas. <i>Human Pathology</i> , 2015, 46, 532-540.	2.0	43
31	The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. <i>Human Pathology</i> , 2013, 44, 2690-2695.	2.0	42
32	Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131245.	2.5	42
33	Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. <i>Human Pathology</i> , 2013, 44, 1293-1299.	2.0	38
34	Exploiting Human NK Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 3013.	4.8	37
35	Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. <i>Cell Cycle</i> , 2013, 12, 1058-1070.	2.6	36
36	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. <i>Journal of Personalized Medicine</i> , 2022, 12, 1073.	2.5	36

#	ARTICLE	IF	CITATIONS
37	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , 2020, 52, 297-309.	0.6	35
38	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e1-204.e7.	1.6	34
39	Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. <i>Pathology</i> , 2017, 49, 10-18.	0.6	30
40	PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. <i>Pathology Research and Practice</i> , 2021, 226, 153605.	2.3	28
41	Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. <i>PLoS ONE</i> , 2016, 11, e0146302.	2.5	27
42	PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. <i>Leukemia</i> , 2020, 34, 932-937.	7.2	26
43	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	1.8	26
44	Artificial intelligence applications for pre-implantation kidney biopsy pathology practice: a systematic review. <i>Journal of Nephrology</i> , 2022, 35, 1801-1808.	2.0	26
45	MicroRNA expression profiling of Xp11 renal cell carcinoma. <i>Human Pathology</i> , 2017, 67, 18-29.	2.0	25
46	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. <i>Human Pathology</i> , 2014, 45, 2233-2239.	2.0	24
47	Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 864-873.	2.7	24
48	Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. <i>Human Pathology</i> , 2013, 44, 2668-2676.	2.0	23
49	Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Histopathology</i> , 2014, 64, 863-871.	2.9	23
50	PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. <i>Human Pathology</i> , 2019, 90, 54-59.	2.0	23
51	Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis. <i>Head and Neck</i> , 2020, 42, 3018-3030.	2.0	23
52	Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. <i>Human Pathology</i> , 2014, 45, 244-248.	2.0	22
53	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , 2015, 10, e0127908.	2.5	21
54	Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells <i>in vitro</i> and correlating with progression <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 74189-74202.	1.8	21

#	ARTICLE	IF	CITATIONS
55	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 680973.	4.8	20
56	Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. <i>Urology</i> , 2014, 83, 1444.e1-1444.e6.	1.0	19
57	TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. <i>Modern Pathology</i> , 2022, 35, 376-385.	5.5	19
58	Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors. <i>Cancers</i> , 2021, 13, 2441.	3.7	19
59	An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. <i>Oncotarget</i> , 2014, 5, 5218-5233.	1.8	19
60	Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection. <i>Histopathology</i> , 2015, 66, 262-269.	2.9	15
61	Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2021, 12, 803014.	4.8	13
62	Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 21-27.	2.8	12
63	Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture). <i>Hla</i> , 2019, 93, 185-194.	0.6	11
64	Pediatric Tumors-Mediated Inhibitory Effect on NK Cells: The Case of Neuroblastoma and Wilms's Tumors. <i>Cancers</i> , 2021, 13, 2374.	3.7	11
65	Wilms's Tumor Primary Cells Display Potent Immunoregulatory Properties on NK Cells and Macrophages. <i>Cancers</i> , 2021, 13, 224.	3.7	11
66	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Human Pathology</i> , 2015, 46, 761-766.	2.0	10
67	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. <i>International Journal of Biological Markers</i> , 2017, 32, 243-247.	1.8	10
68	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 269-273.	2.4	10
69	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. <i>British Journal of Pharmacology</i> , 2020, 177, 2889-2903.	5.4	10
70	Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 677-685.	2.8	9
71	Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. <i>Urology</i> , 2016, 92, 51-56.	1.0	9
72	Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?. <i>Frontiers in Immunology</i> , 2019, 10, 3140.	4.8	9

#	ARTICLE	IF	CITATIONS
73	Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2175-2185.	4.1	8
74	Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review. <i>Diagnostic Cytopathology</i> , 2022, 50, 313-323.	1.0	8
75	Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 316-323.	1.2	6
76	Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 695-701.	2.8	5
77	HLA-G expression in melanomas. <i>International Reviews of Immunology</i> , 2021, 40, 330-343.	3.3	5
78	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 336-336.	1.6	3
79	Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology. <i>BJU International</i> , 2018, 122, 914-915.	2.5	2
80	Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding protein-3 expression. <i>International Journal of Urology</i> , 2019, 26, 678-679.	1.0	2
81	PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 300-300.	1.6	1
82	Non-small cell lung cancer: land of conquest for immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 5184-5185.	1.4	0
83	Oncocytic papillary renal cell carcinoma: potential pitfall in small enucleation. <i>Pathologica</i> , 2012, 104, 98-100.	3.4	0